Smartlab Europe

Clinical Trials

AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ in Atopic Dermatitis

AbbVie at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15 mg or 30 mg; once daily) monotherapy achieved improvement in additional measures of skin clearance...

Baxter Supports New Study Showing Blood Purification with Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients

Baxter International Inc., a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood...

LabCorp Transforms the Clinical Trial Experience And Streamlines the Druag Development Process

LabCorp , a leading global life sciences company that is focused on advancing health and guiding patient care decisions, announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This...

GSK presents positive clinical data on maternal and older adults RSV candidate vaccines

GSK announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress. RSV is...

Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been...

Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials

At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our...

Kodiak begins three phase 3 studies of anti-VEGF antibody biopolymer conjugate, KSI-301 to treat DME and macular edema due to retinal vein occlusion

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER and BEACON studies, three pivotal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »